SAN FRANCISCO and SUZHOU, China, Jan. 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced a collaboration and exclusive license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to advance the development of IBI3009, a novel DLL3-targeted antibody drug conjugate (ADC) candidate. IBI3009 has already obtained IND approvals in Australia, China, and the U.S., with the first patient for the Phase 1 study dosed in December 2024. This collaboration aims to bring innovative treatment options to patients with advanced small cell lung cancer.

IBI3009: A potentially best-in-class DLL3 ADC Candidate

We want to hear from you For general questions or concerns, email [email protected]